Menu Search
Equities

Align Technology Inc

ALGN:NSQ

Align Technology Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)258.28
  • Today's Change5.27 / 2.08%
  • Shares traded149.49k
  • 1 Year change-18.78%
  • Beta1.6343
Data delayed at least 15 minutes, as of Sep 19 2024 16:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Align Technology Inc grew revenues 3.42% from 3.73bn to 3.86bn while net income improved 23.09% from 361.57m to 445.05m.
Gross margin69.82%
Net profit margin11.34%
Operating margin16.21%
Return on assets7.27%
Return on equity12.09%
Return on investment10.96%
More ▼

Cash flow in USDView more

In 2023, Align Technology Inc did not generate a significant amount of cash. However, the company earned 785.78m from its operations for a Cash Flow Margin of 20.34%. In addition the company used 195.94m on investing activities and also paid 598.34m in financing cash flows.
Cash flow per share7.75
Price/Cash flow per share32.20
Book value per share50.31
Tangible book value per share42.68
More ▼

Balance sheet in USDView more

Align Technology Inc uses little or no debt in its capital structure.
Current ratio1.18
Quick ratio1.06
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 26.07%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)3.39
EPS (TTM) vs
TTM 1 year ago		45.11
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.